Fazirsiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease findings from the SEQUOIA phase 2 trial
Ann Med Surg (Lond). 2025 May 30;87(7):4014-4016. doi: 10.1097/MS9.0000000000003393. eCollection 2025 Jul. ABSTRACT Alpha-1 antitrypsin deficiency (AATD) is a prevalent autosomal recessive disorder affecting approximately …